Literature DB >> 7977081

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications.

J D Boehrer1, D J Kereiakes, F I Navetta, R M Califf, E J Topol.   

Abstract

Mesh:

Substances:

Year:  1994        PMID: 7977081     DOI: 10.1016/0002-9149(94)90474-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  7 in total

Review 1.  Developments in antithrombotic therapy: state of the art anno 1996.

Authors:  H ten Cate; M T Nurmohamed; J W ten Cate
Journal:  Pharm World Sci       Date:  1996-12

Review 2.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

3.  Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

Review 4.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

Review 5.  The efficacy and safety of perioperative antiplatelet therapy.

Authors:  J Christopher Merritt; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2002-04       Impact factor: 2.300

Review 6.  The efficacy and safety of perioperative antiplatelet therapy.

Authors:  J Christopher Merritt; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

Review 7.  Abciximab. An updated review of its use in ischaemic heart disease.

Authors:  R H Foster; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.